This inventor holds 2 USPTO granted patents. Top assignee: Genetics Institute, Inc.. Active years: 1990-1997.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 1990-1997
Title: The Innovations of Benjamin S. Isaacs
Introduction
Benjamin S. Isaacs is a notable inventor based in Tewksbury, MA (US). He has made significant contributions to the field of pharmaceutical formulations, particularly in the development of osteogenic proteins and thrombolytic agents. With a total of 2 patents, his work has had a considerable impact on medical science.
Latest Patents
Isaacs' latest patents include innovative pharmaceutical formulations that focus on osteogenic proteins and plasminogen activator proteins. These formulations are designed for intravenous bolus injection, providing thrombolytic proteins, especially 'second generation' tPA molecules, in relatively high concentrations while maintaining low levels of excipients. This advancement is crucial for enhancing the efficacy of thrombolytic therapies.
Career Highlights
Isaacs is associated with Genetics Institute, Inc., where he has been instrumental in advancing research in pharmaceutical sciences. His expertise in the formulation of complex proteins has positioned him as a key figure in the development of new therapeutic strategies.
Collaborations
Throughout his career, Isaacs has collaborated with talented individuals such as Himakshi Patel and Richard A. Kenley. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Benjamin S. Isaacs is a distinguished inventor whose work in pharmaceutical formulations has paved the way for advancements in medical treatments. His contributions continue to influence the field and improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
